Royalty Pharma (RPRX) Corporate presentation summary

Market position and industry trends

• Holds a leading 48% share of the biopharma royalty market from 2020–2025, with a diversified portfolio spanning over 50 approved and development-stage products.

• The royalty funding market is expanding rapidly, driven by growing capital needs, industry fragmentation, and scientific innovation, with annual announced value rising from $0.08bn in 1997 to $10bn in 2025.

• Synthetic royalties are a key growth driver, with a 37% CAGR and significant underpenetration in biopharma funding, representing only ~5% of capital raised from 2021–2025.

• China is emerging as a significant source of royalty creation due to increased licensing activity and a less developed capital market.

• Megatrends such as global innovation, R&D fragmentation, and large capital requirements (> $1 trillion over the next decade) are fueling royalty market growth.

Investment approach and risk management

• Employs a highly selective, flexible investment approach, focusing on products with strong scientific rationale and commercial potential, with only ~2% of initial reviews resulting in transactions.

• Targets attractive returns above cost of capital, with a long-term investment horizon and rigorous due diligence process leveraging internal and external expertise.

• Deployed ~$27bn in capital since 2012, with 65% in approved products and 35% in development-stage therapies, prioritizing post-proof-of-concept investments.

• Maintains a low-risk portfolio, with 87% of invested capital in approved products and a ~90% success rate for development-stage investments.

• Proven ability to identify products that outperform consensus sales estimates, generating attractive returns under a range of commercial scenarios.

Financial performance and outlook

• Delivered consistent double-digit growth since IPO, with 2025 Portfolio Receipts of $3.3bn and Adjusted EBITDA margins above 91%.

• Portfolio Cash Flow per share grew at a 15% CAGR from 2020 to 2025, with a path to >$7.50 per share by 2030, representing a 55% increase from 2025.

• Average annual ROIC of 14.9% and ROIE of 21.5% from 2019–2025, with >90% of transactions since 2020 exceeding cost of capital.

• Significant financial capacity with ~$30bn projected through 2030, supporting at least $2.0–2.5bn in annual royalty acquisitions, share repurchases, and dividends.

• Clear path to substantial shareholder value, targeting mid-teens annual total shareholder return and continued best-in-class pharma diversification.